Marc Stapley A.'s most recent trade in Veracyte Inc was a trade of 138,051 Common Stock done at an average price of $36.6 . Disclosure was reported to the exchange on June 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.60 per share. | 02 Jun 2026 | 138,051 | 578,545 (1%) | 0% | 36.6 | 5,052,667 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.12 per share. | 02 Jun 2026 | 138,051 | 440,494 (0%) | 0% | 50.1 | 6,919,585 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2026 | 138,051 | 0 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.80 per share. | 02 Jun 2026 | 9,012 | 440,494 (0%) | 0% | 47.8 | 430,774 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 2,987 | 2,987 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 2,987 | 2,987 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2026 | 1,878 | 39,327 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2026 | 92,099 | 449,653 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.28 per share. | 04 Mar 2026 | 26,279 | 357,554 (0%) | 0% | 36.3 | 953,368 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 35.56 per share. | 04 Mar 2026 | 19,244 | 383,833 (0%) | 0% | 35.6 | 684,226 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.69 per share. | 22 Jan 2026 | 15,000 | 52,449 (0%) | 0% | 24.7 | 370,350 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 129.11 per share. | 22 Jan 2026 | 4,325 | 38,749 (0%) | 0% | 129.1 | 558,401 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.96 per share. | 22 Jan 2026 | 3,892 | 44,745 (0%) | 0% | 127.0 | 494,128 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.07 per share. | 22 Jan 2026 | 3,812 | 48,637 (0%) | 0% | 126.1 | 480,579 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 127.92 per share. | 22 Jan 2026 | 1,671 | 43,074 (0%) | 0% | 127.9 | 213,754 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 129.78 per share. | 22 Jan 2026 | 1,300 | 37,449 (0%) | 0% | 129.8 | 168,714 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 727 | 37,449 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.16 per share. | 02 Dec 2025 | 7,914 | 326,271 (0%) | 0% | 46.2 | 365,310 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 46.90 per share. | 02 Dec 2025 | 4,448 | 321,823 (0%) | 0% | 46.9 | 208,613 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 47.35 per share. | 02 Dec 2025 | 3,220 | 318,603 (0%) | 0% | 47.3 | 152,462 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.41 per share. | 04 Sep 2025 | 7,667 | 334,185 (0%) | 0% | 30.4 | 233,133 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.11 per share. | 02 Sep 2025 | 7,914 | 341,852 (0%) | 0% | 30.1 | 238,291 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.74 per share. | 02 Jun 2025 | 9,399 | 349,237 (0%) | 0% | 26.7 | 251,329 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 90,601 | 358,636 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.82 per share. | 04 Mar 2025 | 28,189 | 292,543 (0%) | 0% | 32.8 | 925,248 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 33.91 per share. | 04 Mar 2025 | 23,414 | 269,129 (0%) | 0% | 33.9 | 794,009 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.37 per share. | 04 Mar 2025 | 1,094 | 268,035 (0%) | 0% | 34.4 | 37,599 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 67,277 | 375,329 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.84 per share. | 27 Feb 2025 | 34,273 | 341,056 (0%) | 0% | 33.8 | 1,159,798 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 34.76 per share. | 27 Feb 2025 | 20,324 | 320,732 (0%) | 0% | 34.8 | 706,462 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 3,149 | 3,149 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 2,108 | 36,722 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 538 | 34,614 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 43.37 per share. | 13 Dec 2024 | 5,190 | 307,745 (0%) | 0% | 43.4 | 225,080 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 44.14 per share. | 13 Dec 2024 | 400 | 307,345 (0%) | 0% | 44.1 | 17,657 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.12 per share. | 02 Dec 2024 | 5,748 | 312,935 (0%) | 0% | 44.1 | 253,602 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.55 per share. | 02 Sep 2024 | 5,748 | 318,683 (0%) | 0% | 31.5 | 181,349 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 15 Aug 2024 | 6,250 | 40,326 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2024 | 6,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.27 per share. | 15 Aug 2024 | 3,959 | 34,657 (0%) | 0% | 126.3 | 499,903 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 125.28 per share. | 15 Aug 2024 | 1,110 | 38,616 (0%) | 0% | 125.3 | 139,061 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 123.98 per share. | 15 Aug 2024 | 600 | 39,726 (0%) | 0% | 124.0 | 74,388 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 126.91 per share. | 15 Aug 2024 | 581 | 34,076 (0%) | 0% | 126.9 | 73,735 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.75 per share. | 02 Jun 2024 | 5,746 | 323,994 (0%) | 0% | 20.8 | 119,230 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,716 | 34,076 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 1,246 | 1,246 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 15 May 2024 | 6,250 | 38,610 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2024 | 6,250 | 6,250 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 112.91 per share. | 15 May 2024 | 2,200 | 34,360 (0%) | 0% | 112.9 | 248,402 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 111.82 per share. | 15 May 2024 | 2,050 | 36,560 (0%) | 0% | 111.8 | 229,231 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 113.68 per share. | 15 May 2024 | 2,000 | 32,360 (0%) | 0% | 113.7 | 227,360 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 11,780 | 335,711 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 15 Mar 2024 | 5,971 | 329,740 (0%) | 0% | 21.1 | 125,988 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 114,724 | 323,931 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.00 per share. | 02 Mar 2024 | 13,286 | 209,207 (0%) | 0% | 24 | 318,864 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 6,250 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc A. Stapley | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 29 Feb 2024 | 6,250 | 38,610 (0%) | 0% | 32 | 200,000 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 88.76 per share. | 29 Feb 2024 | 2,437 | 36,173 (0%) | 0% | 88.8 | 216,308 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 91.21 per share. | 29 Feb 2024 | 2,313 | 32,360 (0%) | 0% | 91.2 | 210,969 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Sale of securities on an exchange or to another person at price $ 90.54 per share. | 29 Feb 2024 | 1,500 | 34,673 (0%) | 0% | 90.5 | 135,810 | Common Stock |
| Glaukos Corp | Stapley Marc A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,082 | 32,398 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 1,044 | 32,360 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corp | Marc Stapley A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | Marc Stapley A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.28 per share. | 14 Dec 2023 | 10,000 | 41,316 (0%) | 0% | 7.3 | 72,750 | Common Stock |
| Glaukos Corp | A. Stapley Marc | Director | Sale of securities on an exchange or to another person at price $ 75.61 per share. | 14 Dec 2023 | 9,206 | 38,360 (0%) | 0% | 75.6 | 696,066 | Common Stock |
| Glaukos Corp | Marc Stapley A. | Director | Sale of securities on an exchange or to another person at price $ 76.35 per share. | 14 Dec 2023 | 7,044 | 31,316 (0%) | 0% | 76.3 | 537,809 | Common Stock |
| Glaukos Corp | Stapley Marc A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 6,250 | 18,750 | - | - | Stock Option (Right to Buy) | |
| Glaukos Corp | A. Stapley Marc | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.00 per share. | 14 Dec 2023 | 6,250 | 47,566 (0%) | 0% | 32 | 200,000 | Common Stock |
| Veracyte Inc | A. Stapley Marc | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.54 per share. | 02 Dec 2023 | 3,203 | 221,882 (0%) | 0% | 26.5 | 85,008 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.72 per share. | 02 Jun 2023 | 3,203 | 227,696 (0%) | 0% | 26.7 | 85,584 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 3,230 | 31,316 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 128,869 | 128,869 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 78,044 | 230,899 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 02 Mar 2023 | 6,029 | 152,855 (0%) | 0% | 24.1 | 145,299 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,900 | 28,086 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.14 per share. | 02 Dec 2022 | 1,012 | 158,299 (0%) | 0% | 29.1 | 29,490 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.18 per share. | 02 Sep 2022 | 1,012 | 159,311 (0%) | 0% | 19.2 | 19,410 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 16.33 per share. | 10 Jun 2022 | 60,000 | 159,761 (0%) | 0% | 16.3 | 980,094 | Common Stock |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2022 | 4,364 | 26,186 (0%) | 0% | 0 | Common Stock | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.23 per share. | 02 Jun 2022 | 4,047 | 99,761 (0%) | 0% | 18.2 | 73,777 | Common Stock |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 103,026 | 103,026 | - | - | Stock Option (right to buy) | |
| Veracyte Inc | Marc A. Stapley | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 56,537 | 103,808 (0%) | 0% | 0 | Common Stock | |
| Glaukos Corp | Marc A. Stapley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 1,758 | 21,822 (0%) | 0% | 0 | Common Stock |